share_log

Cantor Fitzgerald Reiterates Overweight on Aptose Biosciences, Maintains $38 Price Target

Benzinga ·  Sep 7, 2023 10:33

Cantor Fitzgerald analyst Li Watsek reiterates Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $38 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment